LifeSci Capital downgraded Aeglea BioTherapeutics to Market Perform from Outperform and removed the firm’s price target after the company reported interim results from the Phase 1/2 study with pegtarviliase, or AGLE-177, for homocystinuria, or HCU. Aeglea announced that it is exploring strategic alternatives after the trial disappointed in the third treatment cohort, the firm noted.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AGLE:
- Aeglea BioTherapeutics price target removed at H.C. Wainwright
- Aeglea BioTherapeutics downgraded to Hold from Buy at JonesResearch
- Aeglea BioTherapeutics exploring strategic alternatives
- Aeglea BioTherapeutics announces interim Phase 1/2 results of pegtarviliase
- Aeglea BioTherapeutics reports Q4 revenue $200K, consensus $60K
